HI-511 overcomes melanoma drug resistance <i>via</i> targeting AURKB and BRAF V600E
Xiaoyu Chang, Tianshun Zhang, Qiushi Wang, Moeez Rathore, Kanamata Reddy, Hanyong Chen, Seung Ho Shin, Wei-Ya Ma, Ann M. Bode, Zigang Dong
Abstract
AURKB is a potential target for melanoma treatment. HI-511, a novel dual-target inhibitor against both AURKB and BRAF V600E, could achieve durable suppression of melanoma growth, even drug-resistant melanoma growth.
Topics & Concepts
MelanomaCancer researchDrugDrug resistanceMedicinePharmacologyChemistryBiologyGeneticsMelanoma and MAPK PathwaysCytokine Signaling Pathways and InteractionsCancer Mechanisms and Therapy